Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12817414 | 0.87 | TTR (0.50) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL8410940 | 0.84 | TTR (0.48) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL6720850 | 0.80 | TTR (0.50) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL7929410 | 0.80 | TTR (0.43) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL7929422 | 0.80 | TTR (0.50) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL7932602 | 0.80 | TTR (0.43) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL7930045 | 0.80 | TTR (0.50) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL1686874 | 0.79 | TTR (0.47) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL10891717 | 0.78 | TTR (0.48) | TTRALBMEN1KMT2ALMNA | |
| SCHEMBL22897457 | 0.76 | TDP1 (0.47) | TTRALBMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011367-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| CN-108658733-B | Preparation method of 2,4, 6-triiodoresorcinol | 国药集团化学试剂有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-108658733-A | A kind of preparation method of 2,4,6- triiodos resorcinol | 国药集团化学试剂有限公司 | 2018-10-16 | — | — | CN | claimed |
| WO-2002003938-A1 | IODO-CONTAINING ORGANIC COUPLERS FOR USE IN OXIDATIVE HAIR DYEING | CLAIROL INCORPORATED (US) | 2002-01-17 | — | — | WO | claimed |
| US-5372800-A | X-ray contrast coating | STERLING WINTHROP INC. (US) | 1994-12-13 | — | — | US | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11835860-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11835860-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11814408-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-5372800-A | X-ray contrast coating | STERLING WINTHROP INC. (US) | 1994-12-13 | — | — | US | disclosed |
| EP-0617969-A2 | Compositions of iodophenyl esters and iodophenyl sulfonates for visualization of the gastrointestinal tract | NYCOMED IMAGING AS (NO) | 1994-10-05 | — | — | EP | disclosed |
| EP-0617970-A2 | Compositions of iodophenyl esters and iodophenyl sulfonates in film-forming materials for visualization of the gastrointestinal tract | NYCOMED IMAGING AS (NO) | 1994-10-05 | — | — | EP | disclosed |
| US-5336484-A | Contrast compound comprising an iodobenzene ester and a Group 2A metal salt of a carboxylated or sulfonated polysaccharide in a carrier; uniform coating; radiology | STERLING WINTHROP INC. (US) | 1994-08-09 | — | — | US | disclosed |
| US-5318769-A | Compositions of iodophenyl esters for X-ray visualization of the gastrointestinal tract | STERLING WINTHROP INC. (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0240459-A1 | Curable compositions | CIBA-GEIGY AG (CH) | 1987-10-07 | — | — | EP | disclosed |
| US-3927125-A | Method of preparing 2,4,6-triiodoresorcinol | GRINEV ALEXEI NIKOLAEVICH | 1975-12-16 | — | — | US | disclosed |
| US-3927125-A | Method of preparing 2,4,6-triiodoresorcinol | GRINEV ALEXEI NIKOLAEVICH | 1975-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | TTR 872/4885ALB 2167/4885MEN1 3463/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | TTR 1510/4885ALB 920/4885MEN1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.